Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Nagashio, Ryo ^a   Ueda, Junpei ^a   Ryuge, Shinichiro ^a   Nakashima, Hiroyasu ^a   Jiang, Shi Xu ^a   Kobayashi, Makoto ^a   Yanagita, Kengo ^a   Katono, Ken ^a   Satoh, Yukitoshi ^a   Masuda, Noriyuki ^a   Murakumo, Yoshiki ^a   Hachimura, Kazuo ^a   Sato, Yuichi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; MUC5B PROTEIN, HUMAN; MUCIN 5B; TTF1 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-5B; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS;

EID: 84924037490     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08649     Document Type: Article

References (33)

1. Jemal, A. et al. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. van Rens, M. T., de la Riviere, A. B. & Elbers, H. R. van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117, 374-379 (2000).
3. Farhat, F. S. & Houhou, W. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther. Adv. Med. Oncol. 5, 249-270 (2013).
4. Huang, C. L., Yokomise, H., Fukushima, M. & Kinoshita, M. Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol. 2, 289-299 (2006).
5. Sandler, A. Bevacizumab in non-small cell lung cancer. Clin. Cancer Res. 13, s4613-s4616 (2007).
6. Herbst, R. S. et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25, 4743-4750 (2007).
7. Hirohashi, S., Watanabe, M., Shimosato, Y. & Sekine, T. Monoclonal antibody reactive with the sialyl-sugar residue of a high molecular weight glycoprotein in sera of cancer patients. Gann 75, 485-488 (1984).
8. Nagashio, R. et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer 69, 54-59 (2010).
9. Kobayashi, M. et al. CAXII Is a sero-diagnostic marker for lung cancer. PLoS One 7, e33952 (2012).
10. Desseyn, J. L., Tetaert, D. & Gouyer, V. Architecture of the large membranebound mucins. Gene 410, 215-222 (2008).
11. Thornton, D. J., Rousseau, K. & McGuckin, M. A. Structure and function of the polymeric mucins in airways mucus. Ann. Rev. Physiol. 70, 459-486 (2008).
12. Sónõra, C. et al. Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues. J. Histochem. Cytochem. 54, 289-299 (2006).
13. Jonckheere, N. et al. The mouse Muc5b mucin gene is transcriptionally regulated by thyroid transcription factor-1 (TTF-1) and GATA-6 transcription factors. FEBS. J. 278, 282-294 (2011).
14. Hollingsworth,M.A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4, 45-60 (2004).
15. Baldus, S. E., Engelmann, K. & Hanisch, F. G. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci. 41, 189-231 (2004).
16. Kim, Y. S. Mucin glycoproteins in colonic neoplasia. Keio J. Med. 47, 10-18 (1998).
17. Williams, O. W., Sharafkhaneh, A., Kim, V., Dickey, B. F. & Evans, C. M. Airway mucus: From production to secretion. Am. J. Respir. Cell Mol. Biol. 34, 527-536 (2006).
18. Perrais, M. et al. Aberrant expression of human mucin gene MUC5B in gastric carcinoma and cancer cells. Identification and regulation of a distal promoter. J. Biol. Chem. 276, 15386-15396 (2001).
19. Copin, M. C. et al. Normal respiratory mucosa, precursor lesions and lung carcinomas: differential expression of human mucin genes. Front. Biosci. 6, D1264-D1275 (2001).
20. Yu, C. J. et al. Overexpression of MUC5 genes is associated with early postoperative metastasis in non-small-cell lung cancer. Int. J. Cancer 69, 457-465 (1996).
21. Copin, M. C. et al. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum. Pathol. 32, 274-281 (2001).
22. Zhang, Z. Q., Zhu, Z. X., Bai, C. X. & Chen, Z. H. Aquaporin 5 expression increases mucin production in lung adenocarcinoma. Oncol. Rep. 25, 1645-1650 (2011).
23. Valque, H., Gouyer, V., Gottrand, F. & Desseyn, J. L. MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS One 7, e46699 (2012).
24. Lau, S. K., Luthringer, D. J. & Eisen, R.N. Thyroid transcription factor-1: a review. Appl. Immunohistochem. Mol. Morphol. 10, 97-102 (2002).
25. Maeda, Y., Davé, V. & Whitsett, J. A. Transcriptional control of lung morphogenesis. Physiol. Rev. 87, 219-244 (2007).
26. Maeshima, A. M., Omatsu, M., Tsuta, K., Asamura, H. & Matsuno, Y. Immunohistochemical expression of TTF-1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity. Pathol. Int. 58, 31-37 (2008).
27. Ordónez, N. G. Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature. Appl. Immunohistochem. Mol. Morphol. 20, 525-530 (2012).
28. Martins, S. J. et al. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 64, 105-109 (2009).
29. Travis, W. D. et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, (2004).
30. Goldstraw. et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2, 706-714 (2007).
31. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. TNM classification of malignant tumors, 7th edition. Wiley-Blackwell: NJ, (2009).
32. Nagashio, R. et al. Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 62, 364-373 (2008).
33. Rubin, D. B. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127, 757-763 (1997).